Physician profile
Erin C Crown
NPI 1831535780
$1,239,690.69
in general payments reported to CMS, 2019-2025
33 companies · $362K in 2025
The $362K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $202K · 2023: $361K · 2024: $294K · 2025: $362K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $547K · Travel and Lodging: $180K · Consulting Fee: $160K · Honoraria: $96K · Food and Beverage: $35K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $547,059.68 |
| Travel and Lodging | $179,556.68 |
| Consulting Fee | $159,947.65 |
| Honoraria | $96,076.00 |
| Food and Beverage | $34,937.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $395,466.93 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $269,960.83 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $208,686.86 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $147,001.65 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $89,284.90 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $78,198.73 | 2024-2025 | Cobenfy, Sotyktu |
| Supernus Pharmaceuticals, INC. | $21,246.82 | 2021-2025 | Qelbree, Qelbree |
| H. Lundbeck A S | $10,088.00 | 2024 | Abilify Maintena |
| Janssen Scientific Affairs, LLC | $4,840.00 | 2022-2024 | Spravato |
| Janssen Global Services, LLC | $4,780.51 | 2024 | Spravato |
| Lundbeck LLC | $3,742.19 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $2,359.23 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,079.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $961.12 | 2021-2025 | Trintellix |
| Alkermes, INC. | $461.99 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $318.15 | 2022-2025 | Abilify Asimtufii, Rejoyn |
| Ironshore Pharmaceuticals INC. | $244.22 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $172.15 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $162.83 | 2024-2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $145.23 | 2022-2025 | Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $118.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $111.67 | 2021-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $47.82 | 2023-2025 | Fanapt, Hetlioz |
| Indivior INC. | $46.37 | 2024 | Perseris |
| Jazz Pharmaceuticals INC. | $40.36 | 2021 | |
| Eisai INC. | $34.38 | 2021 | |
| Novo Nordisk INC | $31.43 | 2024 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $18.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.34 | 2023 | Quviviq |
| Braintree Laboratories, INC. | $14.14 | 2023 | Sutab, Suflave |
| Corium, LLC | $11.30 | 2023 | Azstarys |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Crown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.